Zacks expects better pricing, product redesigns, and technological advancements to support multiline insurance players including OSCR, RDN, CNO, PLGO, and HMN. The outlook is constructive but lacks quantified impacts (no specific revenue/EPS or guidance changes cited).
Zacks expects better pricing, product redesigns, and technological advancements to support multiline insurance players including OSCR, RDN, CNO, PLGO, and HMN. The outlook is constructive but lacks quantified impacts (no specific revenue/EPS or guidance changes cited).
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.12
Ticker Sentiment
